Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 8/20 | 0.82 |
| ▸ | CTSB | P07858 | 2/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 1/20 | 0.52 |
| ▸ | TACR1 | P25103 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4936394 | 0.96 | TGM2 (0.75) | TGM2CTSBCTSLCTSSCTSK | |
| SCHEMBL9825343 | 0.96 | TGM2 (0.75) | TGM2CTSBCTSLCTSSCTSK | |
| SCHEMBL4935845 | 0.94 | TGM2 (0.73) | TGM2CTSBCTSLCTSSCTSK | |
| SCHEMBL9825926 | 0.91 | TGM2 (0.69) | TGM2CTSBCTSLCTSSCTSK | |
| SCHEMBL9825280 | 0.91 | TGM2 (0.69) | TGM2CTSBCTSLCTSSCTSK | |
| SCHEMBL4929775 | 0.91 | TGM2 (0.68) | TGM2CTSBCTSLCTSSCTSK | |
| SCHEMBL9826613 | 0.91 | TGM2 (0.68) | TGM2CTSBCTSLCTSSCTSK | |
| SCHEMBL13934076 | 0.90 | TGM2 (1.00) | TGM2CTSBCTSLCTSSCTSK | |
| SCHEMBL1103744 | 0.90 | TGM2 (1.00) | TGM2CTSBCTSLCTSSCTSK | |
| SCHEMBL9825959 | 0.89 | TGM2 (0.66) | TGM2CTSBCTSLCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5622712-A | CONSISTS OF A DRUG AND A QUATERNARY AMMONIUM SALT COMPOUND AS A LIPID COMPONENT | SYNTEX (U.S.A.) INC. (US) | 1997-04-22 | — | — | US | claimed |
| EP-0237082-B1 | 3,5-DISUBSTITUTED 4,5-DIHYDROISOXAZOLES AS TRANSGLUTAMINASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1991-05-29 | — | — | EP | claimed |
| US-4912120-A | Containing amine and amide substitution | SYNTEX (U.S.A.) INC. (US) | 1990-03-27 | — | — | US | claimed |
| EP-0237082-A2 | 3,5-disubstituted 4,5-dihydroisoxazoles as transglutaminase inhibitors | SYNTEX (U.S.A.) INC. (US) | 1987-09-16 | — | — | EP | claimed |
| US-20080299170-A1 | Medical Devices and Coatings Therefor | ASTON UNIVERSITY (GB) | 2008-12-04 | — | — | US | disclosed |
| US-6387395-B1 | N-[1, (1-1) -dialkyloxy] - and N- [1, (1-1) -dialkenyloxy]- alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor | EPPSTEIN DEBORAH A (US) | 2002-05-14 | — | — | US | disclosed |
| US-5622712-A | CONSISTS OF A DRUG AND A QUATERNARY AMMONIUM SALT COMPOUND AS A LIPID COMPONENT | SYNTEX (U.S.A.) INC. (US) | 1997-04-22 | — | — | US | disclosed |
| US-5550289-A | FOR DNA TRANSFECTION | SYNTEX (U.S.A.) INC. (US) | 1996-08-27 | — | — | US | disclosed |
| US-5545412-A | USING LIPOPHILIC COMPOUNDS TO TRANSFECT DNA AND FOR DRUG DELIVERY BY FORMING COMPLEXES TO PENETRATE CELLULAR MEMBRANES | SYNTEX (U.S.A.) INC. (US) | 1996-08-13 | — | — | US | disclosed |
| US-5366737-A | Drug delivery, DNA transfection | SYNTEX (U.S.A.) INC. (US) | 1994-11-22 | — | — | US | disclosed |
| US-5208036-A | Complexing a liposomal composition with a quaternary ammonium diether | SYNTEX (U.S.A.) INC. (US) | 1993-05-04 | — | — | US | disclosed |
| US-5049386-A | Drug and DNA delivery | SYNTEX (U.S.A.) INC. (US) | 1991-09-17 | — | — | US | disclosed |
| EP-0237082-B1 | 3,5-DISUBSTITUTED 4,5-DIHYDROISOXAZOLES AS TRANSGLUTAMINASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1991-05-29 | — | — | EP | disclosed |
| US-4946787-A | DOUBLE COATED LIPOSOME COMPLEX MADE UP OF POLYANION AND A LIPID | SYNTEX (U.S.A.) INC. (US) | 1990-08-07 | — | — | US | disclosed |
| US-4929630-A | SKIN DISORDERS, ACNE, 4,5-DIHYDROISOOXAZOLE PEPTIDES | SYNTEX (U.S.A.) INC. (US) | 1990-05-29 | — | — | US | disclosed |
| US-4912120-A | Containing amine and amide substitution | SYNTEX (U.S.A.) INC. (US) | 1990-03-27 | — | — | US | disclosed |
| US-4897355-A | LIPISOME-POLYANION COMPLEX | SYNTEX (U.S.A.) INC. (US) | 1990-01-30 | — | — | US | disclosed |
| EP-0237082-A2 | 3,5-disubstituted 4,5-dihydroisoxazoles as transglutaminase inhibitors | SYNTEX (U.S.A.) INC. (US) | 1987-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080299170-A1 | Medical Devices and Coatings Therefor | F8, HABP2, TFPI | TGM2 16/4885CTSB 683/4885CTSL 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.